Stock 6662 BIOLASCO TAIWAN CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioLASCO Taiwan Co., Ltd.

Equities

6662

TW0006662000

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 27/06/2024 am IST 		5-day change 1st Jan Change
37.4 TWD -0.13% Intraday chart for BioLASCO Taiwan Co., Ltd. +1.08% +12.65%
14/05 BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
20/03 BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,201 977.1 904.1 779.9 764.5 850.3
Enterprise Value (EV) 1 1,098 700.5 733.5 604.6 603.3 706.9
P/E ratio 22.6 x 17.4 x 14.4 x 17.3 x 18.1 x 17.1 x
Yield 3.59% 4.98% 5.67% 5.25% 5.03% 4.97%
Capitalization / Revenue 4.09 x 2.82 x 3.02 x 3.43 x 3.24 x 3.21 x
EV / Revenue 3.74 x 2.02 x 2.45 x 2.66 x 2.56 x 2.67 x
EV / EBITDA 14.5 x 9 x 8.6 x 9.74 x 10.6 x 12 x
EV / FCF 18.7 x 6.16 x -13.5 x 10.6 x 18.3 x 43 x
FCF Yield 5.33% 16.2% -7.42% 9.39% 5.47% 2.32%
Price to Book 3.55 x 2.09 x 1.93 x 1.69 x 1.68 x 1.84 x
Nbr of stocks (in thousands) 23,294 25,612 25,612 25,612 25,612 25,612
Reference price 2 51.57 38.15 35.30 30.45 29.85 33.20
Announcement Date 29/03/19 30/03/20 29/03/21 25/03/22 24/03/23 20/03/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 293.7 346.7 298.9 227.6 235.9 264.7
EBITDA 1 75.56 77.87 85.25 62.07 56.91 58.96
EBIT 1 68.75 70.88 77.57 53.89 49.27 50.76
Operating Margin 23.41% 20.44% 25.95% 23.68% 20.88% 19.18%
Earnings before Tax (EBT) 1 65.74 68.72 78.5 56.44 53.14 61.99
Net income 1 53.13 54.97 62.8 45.15 42.31 49.74
Net margin 18.09% 15.86% 21.01% 19.84% 17.94% 18.79%
EPS 2 2.280 2.190 2.450 1.760 1.650 1.940
Free Cash Flow 1 58.56 113.6 -54.46 56.8 32.98 16.43
FCF margin 19.94% 32.78% -18.22% 24.96% 13.98% 6.21%
FCF Conversion (EBITDA) 77.5% 145.94% - 91.51% 57.96% 27.87%
FCF Conversion (Net income) 110.23% 206.71% - 125.79% 77.96% 33.03%
Dividend per Share 2 1.850 1.900 2.000 1.600 1.500 1.650
Announcement Date 29/03/19 30/03/20 29/03/21 25/03/22 24/03/23 20/03/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 103 277 171 175 161 143
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 58.6 114 -54.5 56.8 33 16.4
ROE (net income / shareholders' equity) 16.1% 13.6% 13.4% 9.73% 9.25% 10.9%
ROA (Net income/ Total Assets) 11.1% 9.59% 8.65% 5.79% 5.38% 5.55%
Assets 1 480.1 573 726.1 780 785.9 895.9
Book Value Per Share 2 14.50 18.20 18.30 18.00 17.80 18.00
Cash Flow per Share 2 3.600 9.640 7.870 7.850 6.580 5.580
Capex 1 4.42 1.94 114 4.23 3.81 1.63
Capex / Sales 1.5% 0.56% 38.28% 1.86% 1.62% 0.62%
Announcement Date 29/03/19 30/03/20 29/03/21 25/03/22 24/03/23 20/03/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIOLASCO TAIWAN CO., LTD. Stock BioLASCO Taiwan Co., Ltd.
+12.65% 29.42M
MODERNA, INC. Stock Moderna, Inc.
+21.45% 46.93B
LONZA GROUP AG Stock Lonza Group AG
+37.63% 39.08B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.38% 38.48B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.03% 31.01B
CELLTRION, INC. Stock Celltrion, Inc.
-13.75% 26.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.02% 25.88B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+36.20% 12.53B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.60% 11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.43% 10.65B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 6662 Stock
  4. Financials BioLASCO Taiwan Co., Ltd.